loading
Schlusskurs vom Vortag:
$59.67
Offen:
$59.58
24-Stunden-Volumen:
572.83K
Relative Volume:
0.28
Marktkapitalisierung:
$11.46B
Einnahmen:
$2.95B
Nettoeinkommen (Verlust:
$523.88M
KGV:
22.21
EPS:
2.69
Netto-Cashflow:
$620.18M
1W Leistung:
+2.42%
1M Leistung:
+9.32%
6M Leistung:
-3.15%
1J Leistung:
-29.36%
1-Tages-Spanne:
Value
$59.26
$60.29
1-Wochen-Bereich:
Value
$56.48
$60.29
52-Wochen-Spanne:
Value
$52.93
$94.85

Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile

Name
Firmenname
Biomarin Pharmaceutical Inc
Name
Telefon
(415) 506-6700
Name
Adresse
105 DIGITAL DRIVE, NOVATO, CA
Name
Mitarbeiter
3,040
Name
Twitter
Name
Nächster Verdiensttermin
2024-10-29
Name
Neueste SEC-Einreichungen
Name
BMRN's Discussions on Twitter

Vergleichen Sie BMRN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
BMRN
Biomarin Pharmaceutical Inc
59.78 11.35B 2.95B 523.88M 620.18M 2.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
475.19 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
571.92 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.46 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
589.03 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.53 31.99B 3.81B -644.79M -669.77M -6.24

Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-03 Fortgesetzt Morgan Stanley Overweight
2025-02-24 Hochstufung Oppenheimer Perform → Outperform
2024-11-15 Eingeleitet Wolfe Research Outperform
2024-10-30 Herabstufung William Blair Outperform → Mkt Perform
2024-10-10 Fortgesetzt Raymond James Outperform
2024-08-20 Hochstufung Bernstein Mkt Perform → Outperform
2024-05-17 Herabstufung Robert W. Baird Outperform → Neutral
2024-05-14 Eingeleitet Evercore ISI Outperform
2023-11-15 Eingeleitet Wells Fargo Overweight
2023-10-23 Hochstufung Bernstein Underperform → Mkt Perform
2023-09-28 Eingeleitet Raymond James Mkt Perform
2023-09-18 Eingeleitet UBS Buy
2023-07-27 Eingeleitet Scotiabank Sector Perform
2023-07-05 Hochstufung BMO Capital Markets Market Perform → Outperform
2023-06-14 Fortgesetzt Credit Suisse Outperform
2023-03-21 Eingeleitet Bernstein Underperform
2023-02-22 Herabstufung Oppenheimer Outperform → Perform
2023-02-21 Eingeleitet Citigroup Neutral
2023-01-30 Eingeleitet BMO Capital Markets Market Perform
2023-01-18 Eingeleitet Canaccord Genuity Hold
2022-10-31 Hochstufung Oppenheimer Perform → Outperform
2022-07-13 Eingeleitet Cantor Fitzgerald Overweight
2022-06-13 Fortgesetzt Wedbush Neutral
2022-04-25 Hochstufung Morgan Stanley Equal-Weight → Overweight
2021-11-22 Hochstufung William Blair Mkt Perform → Outperform
2021-10-07 Fortgesetzt Jefferies Buy
2021-09-09 Hochstufung Stifel Hold → Buy
2021-06-04 Fortgesetzt Robert W. Baird Outperform
2021-04-26 Fortgesetzt Credit Suisse Outperform
2021-03-04 Fortgesetzt Guggenheim Buy
2021-03-01 Hochstufung Evercore ISI In-line → Outperform
2020-08-20 Herabstufung Citigroup Buy → Neutral
2020-08-20 Herabstufung William Blair Outperform → Mkt Perform
2020-08-19 Herabstufung Evercore ISI Outperform → In-line
2020-08-19 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2020-08-19 Herabstufung Stifel Buy → Hold
2020-07-08 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-07-06 Bestätigt Citigroup Buy
2020-01-28 Eingeleitet BMO Capital Markets Market Perform
2020-01-27 Eingeleitet BMO Capital Markets Market Perform
2020-01-24 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2019-11-27 Hochstufung Barclays Equal Weight → Overweight
2019-11-12 Eingeleitet SunTrust Buy
2019-10-17 Fortgesetzt BofA/Merrill Buy
2019-05-23 Fortgesetzt Citigroup Buy
2019-04-09 Fortgesetzt Raymond James Outperform
2019-01-02 Herabstufung Raymond James Outperform → Mkt Perform
2018-12-14 Eingeleitet Wolfe Research Outperform
2018-10-01 Eingeleitet Cantor Fitzgerald Overweight
2018-08-07 Bestätigt Stifel Buy
2018-08-03 Bestätigt Stifel Buy
Alle ansehen

Biomarin Pharmaceutical Inc Aktie (BMRN) Neueste Nachrichten

pulisher
Jul 23, 2025

BioMarin: Less Likely M&A Target As New Rival For Best-Selling Drug Emerges (Rating Downgrade) - Seeking Alpha

Jul 23, 2025
pulisher
Jul 23, 2025

BioMarin Pharmaceutical Inc. Stock Analysis and ForecastOutstanding growth strategies - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Is BioMarin Pharmaceutical Inc. a good long term investmentBreakthrough financial growth - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

What drives BioMarin Pharmaceutical Inc. stock priceAccelerated earnings growth - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

What analysts say about BioMarin Pharmaceutical Inc. stockDouble-digit growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET - WV News

Jul 22, 2025
pulisher
Jul 22, 2025

Investors Still Waiting For A Pull Back In BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - simplywall.st

Jul 22, 2025
pulisher
Jul 19, 2025

BioMarin Bets On Growth, But Competition Keeps Pressure On - Finimize

Jul 19, 2025
pulisher
Jul 17, 2025

BioMarin’s BMN 349 Study: A Potential Game-Changer in Genetic Disorder Treatment - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

Morgan Stanley Sees Rebound Potential in BioMarin (BMRN), Highlights Underappreciated Voxzogo Upside - Yahoo

Jul 17, 2025
pulisher
Jul 16, 2025

Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt? - 富途牛牛

Jul 16, 2025
pulisher
Jul 16, 2025

Looking for a Growth Stock? 3 Reasons Why BioMarin (BMRN) is a Solid Choice - Yahoo Finance

Jul 16, 2025
pulisher
Jul 16, 2025

Wall Street Analysts Think BioMarin (BMRN) Could Surge 70.77%: Read This Before Placing a Bet - Zacks Investment Research

Jul 16, 2025
pulisher
Jul 15, 2025

BioMarin stock maintains Outperform rating at Wolfe Research amid PKU market competition By Investing.com - Investing.com South Africa

Jul 15, 2025
pulisher
Jul 15, 2025

BioMarin stock maintains Outperform rating at Wolfe Research amid PKU market competition - Investing.com Nigeria

Jul 15, 2025
pulisher
Jul 14, 2025

What makes BioMarin Pharmaceutical Inc. stock price move sharplyFree Step-by-Step Investment Guide - beatles.ru

Jul 14, 2025
pulisher
Jul 14, 2025

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - NewsBreak: Local News & Alerts

Jul 14, 2025
pulisher
Jul 13, 2025

BioMarin Pharmaceutical (BMRN) Finalizes the Acquisition of Inozyme Pharma - MSN

Jul 13, 2025
pulisher
Jul 11, 2025

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2025 Earnings Call Transcript - MSN

Jul 11, 2025
pulisher
Jul 11, 2025

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - sharewise.com

Jul 11, 2025
pulisher
Jul 10, 2025

Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance

Jul 10, 2025
pulisher
Jul 09, 2025

10 Best Growth Stocks to Buy With Huge Upside Potential - Insider Monkey

Jul 09, 2025
pulisher
Jul 08, 2025

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock - Yahoo Finance

Jul 08, 2025
pulisher
Jul 03, 2025

BioMarin’s BMN 349 Study: A New Frontier in Genetic Mutation Treatment - TipRanks

Jul 03, 2025
pulisher
Jul 03, 2025

BioMarin stock rating initiated at Overweight by Morgan Stanley on Voxzogo growth - Investing.com

Jul 03, 2025
pulisher
Jul 02, 2025

The Best Biotech Stocks to Buy - Morningstar

Jul 02, 2025
pulisher
Jul 01, 2025

BioMarin Pharmaceutical completes acquisition of Inozyme Pharma - grafa.com

Jul 01, 2025
pulisher
Jul 01, 2025

BioMarin Pharmaceutical Closes Acquisition of Inozyme Pharma - MarketScreener

Jul 01, 2025
pulisher
Jul 01, 2025

BioMarin Acquires Inozyme for $270M, Gains Late-Stage Enzyme Therapy for Untreated Rare Disease - Stock Titan

Jul 01, 2025
pulisher
Jul 01, 2025

BioMarin Announces Completion of Acquisition of Inozyme - ETX View

Jul 01, 2025
pulisher
Jun 30, 2025

BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) dropped from Russell 1000 Defensive Index - MarketScreener

Jun 30, 2025
pulisher
Jun 28, 2025

BioMarin’s ROCTAVIAN Shows Sustained Efficacy, Safety Over 5 Years for Severe Hemophilia A - MSN

Jun 28, 2025
pulisher
Jun 28, 2025

11 Most Undervalued US Stocks According to Analysts - Insider Monkey

Jun 28, 2025
pulisher
Jun 26, 2025

Pfizer's bleeding disorder therapy succeeds in trial with patients with certain antibodies - Reuters

Jun 26, 2025
pulisher
Jun 25, 2025

BioMarin stock maintains Buy rating at Jefferies amid exclusivity battle - Investing.com

Jun 25, 2025
pulisher
Jun 24, 2025

Landmark 5-Year Data: BioMarin Gene Therapy Transforms Hemophilia Treatment with 81% Success Rate - Stock Titan

Jun 24, 2025

Finanzdaten der Biomarin Pharmaceutical Inc-Aktie (BMRN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$23.62
price up icon 3.26%
$36.56
price up icon 1.51%
$103.38
price down icon 0.14%
$27.57
price down icon 1.58%
$114.12
price down icon 0.42%
biotechnology ONC
$296.06
price up icon 0.42%
Kapitalisierung:     |  Volumen (24h):